Xospata bags European Commission approval

25th October 2019 Uncategorised 0

The decision was based on the Phase III ADMIRAL trial, in which one-year survival rates shot to 37% for patients who received Xospata, compared to 17% for patients who received salvage chemotherapy.

More: Xospata bags European Commission approval
Source: News